Menu Back toReal-World Response: Harnessing Electronic Health Records to Develop Robust Clinical Endpoints in Solid Tumors

DIA 2021 Global Annual Meeting


Real-World Response: Harnessing Electronic Health Records to Develop Robust Clinical Endpoints in Solid Tumors

Session Chair(s)

Michael W. Lu, PharmD

Michael W. Lu, PharmD

  • Platform Strategy Leader, RWD, Personalized Healthcare Oncology
  • Genentech, A Member of the Roche Group, United States
RECIST-based response is an established endpoint in clinical trials, but how do you assess response in routine patient care? This session presents efforts to develop a real-world response endpoint and its utility in clinical development.
Learning Objective : Describe the utility of measuring treatment response in clinical trials and challenges of accessing it in routine clinical care; Discuss methods, data elements, and rigor needed to evaluate this endpoint and future implications for clinical development.

Speaker(s)

Ariel  Bourla, MD, PhD

Real-World Response: Harnessing Electronic Health Records to Develop Robust Clinical Endpoints in Solid Tumors

Ariel Bourla, MD, PhD

  • Medical Director
  • Flatiron Health, United States
Michael W. Lu, PharmD

Application of Real-World Response in Prospective Studies

Michael W. Lu, PharmD

  • Platform Strategy Leader, RWD, Personalized Healthcare Oncology
  • Genentech, A Member of the Roche Group, United States
Gregory  Riely, MD, PhD

Exploring Real-World Response and Progression Free Survival in the AACR GENIE Biopharma Collaborative

Gregory Riely, MD, PhD

  • Vice Chair, Clinical Research, Department of Medicine
  • Memorial Sloan Kettering Cancer Center, United States